CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 80 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $483,732 | -91.3% | 10,800 | -90.9% | 0.00% | -92.3% |
| Q1 2024 | $5,564,773 | -19.0% | 118,880 | -38.4% | 0.01% | -18.8% |
| Q4 2023 | $6,870,534 | -42.5% | 193,101 | -52.0% | 0.02% | -50.0% |
| Q3 2023 | $11,954,082 | +624.7% | 401,953 | +339.1% | 0.03% | +700.0% |
| Q2 2023 | $1,649,461 | +219.0% | 91,535 | +184.3% | 0.00% | +300.0% |
| Q1 2023 | $517,132 | +14.8% | 32,200 | +30.8% | 0.00% | 0.0% |
| Q4 2022 | $450,400 | -1.4% | 24,612 | +5.8% | 0.00% | -50.0% |
| Q3 2022 | $457,000 | -47.6% | 23,256 | -50.2% | 0.00% | -33.3% |
| Q2 2022 | $872,000 | -67.1% | 46,745 | -61.3% | 0.00% | -62.5% |
| Q1 2022 | $2,651,000 | -32.0% | 120,777 | -12.0% | 0.01% | 0.0% |
| Q4 2021 | $3,900,000 | +26.7% | 137,292 | -6.2% | 0.01% | +14.3% |
| Q3 2021 | $3,079,000 | +40.5% | 146,292 | +25.8% | 0.01% | +40.0% |
| Q2 2021 | $2,192,000 | +147.7% | 116,310 | +100.7% | 0.01% | +150.0% |
| Q1 2021 | $885,000 | +16.3% | 57,944 | +7.5% | 0.00% | 0.0% |
| Q4 2020 | $761,000 | +79.5% | 53,911 | +99.1% | 0.00% | 0.0% |
| Q3 2020 | $424,000 | -55.0% | 27,077 | -49.7% | 0.00% | -60.0% |
| Q2 2020 | $943,000 | – | 53,812 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 479,681 | $21,484,912 | 8.12% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $6,315,390 | 7.68% |
| STEMPOINT CAPITAL LP | 551,095 | $24,683,545 | 7.25% |
| EcoR1 Capital, LLC | 4,155,375 | $186,119,246 | 5.69% |
| ACUTA CAPITAL PARTNERS, LLC | 135,141 | $6,052,965 | 5.10% |
| First Light Asset Management, LLC | 1,200,508 | $53,770,753 | 4.71% |
| Ikarian Capital, LLC | 588,818 | $26,373,158 | 4.59% |
| Paradigm Biocapital Advisors LP | 2,513,302 | $112,570,797 | 4.31% |
| MPM BioImpact LLC | 557,184 | $24,956,271 | 3.88% |
| Cormorant Asset Management, LP | 1,350,000 | $60,466,500 | 3.49% |